Prescient Therapeutics (ASX:PTX) secured investigational new drug clearance from the US Food and Drug Administration to conduct a phase two trial of PTX-100 in patients with relapsed and refractory cutaneous T-cell lymphomas, according to a Monday filing with the Australian bourse.
The two-part trial will investigate the optimal dose of PTX-100 and its efficacy, the filing said. It will be conducted across 15 global trial sites.
The company's shares fell 4% in recent Friday trade.
Price (AUD): $0.05, Change: $-0.002, Percent Change: -4.08%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.